Management of dental-oral procedures in patients with hereditary angioedema due to C1 inhibitor deficiency.

BACKGROUND Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1-INH) has considerable implications for dental health care providers, since dental procedures may trigger severe and even life-threatening episodes. The aim of the present study was to analyze the efficacy and safety of premedication with attenuated androgens (AAs), plasma-derived human C1 esterase inhibitor concentrate (pdhC1INH), or both to prevent the development of upper airway angioedema after dental-oral procedures in patients with HAE-C1-INH. MATERIAL AND METHODS All dental-oral procedures performed on patients with HAE-C1-INH who were followed up at La Paz University Hospital, Madrid, Spain were reviewed. Demographic data, maintenance treatment, preprocedure prophylaxis, disease severity, and occurrence of upper airway angioedema were recorded. RESULTS Twenty-four patients (14 male/10 female; mean age, 42.6 years) underwent 66 procedures. Most procedures were performed on patients with severe HAE-C1-INH (20 procedures) or moderate HAE-C1-INH (26 procedures). Only 9 procedures were performed without short-term prophylaxis. Mild upper airway angioedema developed after 3 procedures performed without short-term prophylaxis in patients with minimal or asymptomatic HAE-C1-INH. A statistically significant association was found between development of mild postprocedure upper airway angioedema and lack of maintenance treatment with AA, lack of increased dose of preprocedure AA, and failure to administer preprocedure pdhC1INH (P = .002, Fisher exact test). CONCLUSIONS Increased doses of prophylactic AA, administration of pdhC1INH, or both were good options for ambulatory management of dental-oral procedures in patients with HAE-C1-INH. Prophylaxis with pdC1INH or increased doses of AA is advisable before dental-oral procedures, even in patients with low disease severity.

[1]  K. Bork,et al.  Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. , 2011, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[2]  W. Lumry,et al.  Pre-procedure Administration of C1 Esterase Inhibitor (Human) (Cinryze™) for the Prevention of Hereditary Angioedema (HAE) Attacks after Medical, Dental, or Surgical Procedures , 2011 .

[3]  T. Klingebiel,et al.  Pharmacokinetic analysis of human plasma–derived pasteurized C1‐inhibitor concentrate in adults and children with hereditary angioedema: a prospective study , 2010, Transfusion.

[4]  J. Clotet,et al.  Short‐term prophylactic treatment of hereditary angioedema with icatibant , 2010, Allergy.

[5]  M. Gompels,et al.  C1 inhibitor deficiency: consensus document , 2005, Clinical and experimental immunology.

[6]  A. Tordai,et al.  Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond , 2004, Journal of Allergy and Clinical Immunology.

[7]  William H. Yang,et al.  Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. , 2004, The Journal of allergy and clinical immunology.

[8]  J. Lindner,et al.  Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert® P) in hereditary angioedema: a review , 2003 .

[9]  M. Cicardi,et al.  How do we treat patients with hereditary angioedema. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[10]  K. Bork,et al.  Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. , 2003, Journal of the American Dental Association.

[11]  K. Bork,et al.  Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. , 2003, Archives of internal medicine.

[12]  M. Abinun,et al.  Current management of hereditary angio-oedema (C'1 esterase inhibitor deficiency). , 2002, Journal of clinical pathology.

[13]  K. Bork,et al.  Asphyxiation by laryngeal edema in patients with hereditary angioedema. , 2000, Mayo Clinic proceedings.

[14]  H. Farkas,et al.  The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. , 1999, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[15]  Maves Kk,et al.  Tonsillectomy in a patient with hereditary angioedema after prophylaxis with C1 inhibitor concentrate. , 1994 .

[16]  J. Weiner,et al.  C1‐esterase inhibitor concentrate prevents upper airway obstruction in hereditary angio‐oedema , 1994, The Medical journal of Australia.

[17]  M. Cicardi,et al.  Hereditary and Acquired C1‐Inhibitor Deficiency: Biological and Clinical Characteristics in 235 Patients , 1992, Medicine.

[18]  M. Frank,et al.  Oral manifestations and dental management of patients with hereditary angioedema. , 1991, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[19]  J. Hardie,et al.  Potentially fatal hereditary angioedema: a review and case report. , 1990, Journal.

[20]  R. Crosher Intravenous tranexamic acid in the management of hereditary angio-oedema. , 1987, The British journal of oral & maxillofacial surgery.

[21]  R. Grisius,et al.  Hereditary angioedema controlled with danazol. Report of a case. , 1979, Oral surgery, oral medicine, and oral pathology.

[22]  S. A. Danilova,et al.  [Hereditary angioneurotic edema]. , 1979, Klinicheskaia meditsina.

[23]  A. Sheffer,et al.  Tranexamic acid: preoperative prophylactic therapy for patients with hereditary angioneurotic edema. , 1977, The Journal of allergy and clinical immunology.

[24]  J. Atkinson,et al.  Hereditary angioedema: the clinical syndrome and its management. , 1976, Annals of internal medicine.

[25]  H. Pence,et al.  Prophylactic use of epsilon aminocaproic acid for oral surgery in a patient with hereditary angioneurotic edema. , 1974, The Journal of allergy and clinical immunology.

[26]  F. Rosen,et al.  Hereditary Angioneurotic Edema: Two Genetic Variants , 1965, Science.

[27]  W. Osler HEREDITARY ANGIO‐NEUROTIC ŒDEMA , 1888 .

[28]  M. López-Trascasa,et al.  Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. , 2011, Journal of investigational allergology & clinical immunology.

[29]  M. López-Trascasa,et al.  Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. , 2011, Journal of investigational allergology & clinical immunology.

[30]  B. Zuraw Current and future therapy for hereditary angioedema. , 2005, Clinical immunology.

[31]  J. Weiler,et al.  Tonsillectomy in a patient with hereditary angioedema after prophylaxis with C1 inhibitor concentrate. , 1994, Annals of allergy.

[32]  P. Spaeth,et al.  Hereditary angioedema: uncomplicated maxillofacial surgery using short-term C1 inhibitor replacement therapy. , 1993, International archives of allergy and immunology.